ScripThe progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer
ScripWith Bristol-Myers Squibb Co. ’s checkpoint inhibitor Opdivo (nivolumab) having a US FDA PDUFA date of Sept. 24, 2017, for use as a second-line therapy for hepatocellular carcinoma (HCC), and E
ScripIncyte Corp. is gaining an asset from Calithera Biosciences Inc. that may offer an ideal therapeutic complement to the key asset in Incyte’s immuno-oncology pipeline, the Phase III IDO1 inhibito
ScripThe US FDA's accelerated approval of Bristol-Myers Squibb Co. 's PD-1 inhibitor Opdivo for second-line hepatocellular carcinoma paves a path for checkpoint immunotherapies in yet another traditio